Good morning. Fortune senior writer Maria Aspan here.
“We will do anything to survive outside of bankruptcy.” CEO Saundra Pelletier has spent the past year watching her pharma company, Evofem Biosciences, slowly slip to the brink of failure. She also spent the past two months talking to me about her company’s struggles, offering Fortune’s readers a rare window into how top executives manage through—and try to avert—the ultimate business disaster.
Evofem’s shares have been delisted from the Nasdaq, and its sales aren’t growing fast enough to overcome its losses (or its debt load). Last month, the San Diego company parted ways with most of Pelletier’s remaining staff, including members of her C-Suite: her CFO resigned, her chief commercial officer was laid off, and her 35 remaining employees took salary cuts of 20%. (Pelletier’s own salary was slashed by 40%, to $520,000.)
Still, Pelletier isn’t giving up yet. Evofem’s latest round of blood-letting will cut about $4.3 million in expenses, buying her company another few months of operating budget, while she keeps searching for a buyer or investor or another savior.
“We are on life support,” she says. But “there’s nothing I would not do for this company to succeed.”
There are many reasons for Evofem’s current predicament, including some of Pelletier’s own making, as I report in a new profile and investigation for Fortune. The company, which makes a prescription contraceptive gel called Phexxi, has survived expensive regulatory limbo; product setbacks; and even some personal tragedies, including plane crashes and cancer diagnoses.
But the biggest financial challenges facing Evofem—and all the entrepreneurs and executives trying to innovate in its crucial market—involve our broken health care system. It’s part of a much bigger story about how reluctant big drugmakers are to invest in women’s health—and about how much power big insurance companies wield over small pharma companies like Evofem, to block their innovation and growth.
“We’ve never clawed our way back in the public market because now we’ve got to face the insurance companies,” says Al Altomari, the CEO of Agile Therapeutics, another small company that launched a new contraceptive called Twirla in 2020—and quickly ran into some of the same financial obstacles as Evofem.
Check out the full story, which follows Pelletier’s tireless efforts to save her company—while diving into the systemic, industry-wide problems facing Evofem, Agile, and the 73 million U.S. women who are their prospective customers.
Maria Aspan
maria.aspan@fortune.com
@mariaaspan
Upcoming event: The next Fortune Emerging CFO virtual event, “Addressing the Talent Gap with Advanced Technologies,” presented in partnership with Workday (a CFO Daily sponsor), will take place from 11 a.m.-12 p.m. EST on April 12. Matt Heimer, executive editor of features at Fortune, and CFO Daily's Sheryl Estrada will be joined by TELUS International CFO Vanessa Kanu; Alight Solutions CFO Katie Rooney; and Tom Davenport, author, All-in on A.I., President’s Distinguished Professor at Babson College, fellow at MIT Initiative for the Digital Economy, and visiting professor at Saïd Business School, University of Oxford. Click here to learn more and register.
